



NATIONAL CANCER CONGRESS MALAYSIA

Bridging Gaps, Building Hope, Empowering Lives

NATIONAL CANCER CONGRESS MALAYSIA 2025

CONFERENCE PREVIEW

Date: 20 - 22 June 2025

Time: 8:00am – 5:00pm

Venue: Sunway University, Kuala Lumpur



20

Points
awarded
for MMA-
CME/CPD

14

Points
awarded
for MPS-
CPD



National Cancer Congress Malaysia - NCCM



ncc.malaysia



National Cancer Society Malaysia

BRIDGING GAPS, BUILDING HOPE, EMPOWERING LIVES

We are thrilled to announce the launch of the National Cancer Congress Malaysia (NCCM) 2025, a continuation of the groundbreaking initiative which began with highly successful NCCM 2024. Hosted by the National Cancer Society of Malaysia and Sunway University, this congress continues to be a pivotal platform for healthcare professionals, researchers, policymakers, and advocates to share insights, innovations, and best practices in cancer care.

We extend a warm welcome to all of you to join us for NCCM 2025 under the theme “Bridging Gaps, Building Hope, Empowering Lives”, taking place from 20th to 22nd June 2025, at Sunway University, Selangor. This theme is particularly significant as it encapsulates the full spectrum of cancer care, from prevention, screening, and diagnosis to treatment, survivorship, advocacy, and policy.

The congress will feature a diverse range of plenary and scientific sessions where expert speakers will share their insights, research findings, and experiences to inspire and deepen our understanding about cancer care. We encourage everyone to actively participate in the sessions, engage in fruitful discussions, and build connections with fellow attendees. The exchange of ideas and experiences in this conference will contribute to the collective growth and advancement of cancer care in Malaysia.

We warmly welcome everyone to the National Cancer Congress Malaysia 2025, where together we shall continue to build hope and empower lives in the fight against cancer.

THE COMMITTEES

Steering Committee

- Prof. Dr Rosmawati Mohamed
- Prof. Abhimanyu Veerakumarasivam
- Dato’ Dr Saunthari Somasundaram
- Prof. Dr Raja Affendi Raja Ali
- Prof. Elil Renganathan
- Dr Noraryana binti Hassan

Scientific Committee

- Prof. Dr Felicia Chung Fei Lei
- Dr Lau Tze Pheng

Organising Committee

- Kolonel Bersekutu (PA) Assoc. Prof. Dr Murallitharan Munisamy

COMMUNITY PARTNER:



DIAMOND SPONSORS:



SAPPHIRE SPONSORS:



RUBY SPONSORS:



We have been there from the start.

Since 1997, we have worked to transform access to healthcare by putting quality care and treatment within reach so that all people can achieve better health.

28+
years

116+
countries

10M+
patients

- ✓ Access Strategy Consulting
- ✓ Access to Diagnostics Programs
- ✓ Access and Adherence to Treatment Programs
- ✓ Remote Care

axios
TRANSFORMING ACCESS TO HEALTHCARE



Visit us at Booth A4
and at axiosint.com



STRENGTHEN DATA MONITORING & USE

Publicly track National Strategic Plan for Cancer Control Programme key performance indicators, leverage national health data, and mandate cancer reporting from all facilities

IMPROVE PATIENT QUALITY OF LIFE

Implement patient navigation systems and ensure access to psychosocial support

PROMOTE VALUE- BASED MEDICINE

Use patient-centered approaches and care pathways to assess and deliver value in cancer care

ENHANCE GOVERNANCE

Establish a multi-sectoral governance body for cancer control involving health and non-health stakeholders

REFORM CANCER FINANCING

Advocate for increased national cancer budget and innovative public-private partnership financing

Allocate a portion of sin tax and introduce new insurance models like community-based health insurance and portable cancer coverage



KEY FOCUS AREAS



PHARMACEUTICAL ASSOCIATION OF MALAYSIA
C-18-02, 3 Two Square (Dataran 3 2),
No. 2, Jalan 19/1, 46300 Petaling Jaya, Selangor.
T: 03-7960 8322/23 | E: phama@phama.org.my | www.phama.org.my

  
www.phama.org.my

ADVOCACY

Advocate industry-related issues that will directly or indirectly impact the healthcare ecosystem, and serves as a intermediary between the industry and government

INDUSTRY SUPPORT

Develop strategic frameworks to Promote Regulatory Excellence, uphold Ethical Business Practices, and Drive Biopharmaceutical Research and Development

CAPACITY BUILDING

Increase the knowledge and skills of industry players and stakeholders by supporting and organising events on scientific knowledge, work enhancement personal development and more as part of nation-building

STRATEGIC PARTNERSHIPS

Embrace Public-Private Partnerships to create mutually beneficial opportunities and optimise resources with stakeholders who share the same synergies and vision for Malaysia



PHARMACEUTICAL ASSOCIATION OF MALAYSIA
C-18-02, 3 Two Square (Dataran 3 2),
No. 2, Jalan 19/1, 46300 Petaling Jaya, Selangor.
T: 03-7960 8322/23 | E: phama@phama.org.my | www.phama.org.my



Democratizing Access to Biosimilars Across the World

Democratizing access to biosimilars across the globe is not just a goal, but a commitment we take seriously as a company rooted in the world's largest democracy. As a fully integrated, global biosimilars company, we are using our 'lab-to-market' capabilities to serve the need for cost-effective, high quality biosimilars across 120+ countries.

Through our portfolio of affordable monoclonal antibodies for cancer, we are expanding access to life-saving therapies, helping patients receive effective treatment without adding to their financial burden. In diabetes care, our insulins are helping bridge critical treatment gaps by offering more patients access to essential, life-sustaining therapies.

By delivering on our promise of product accessibility, affordability, availability and assurance, Biocon Biologics is transforming healthcare and transforming the lives of millions of patients worldwide.

BIOCON BIOLOGICS AT A GLANCE:

20

Biosimilars in
portfolio

9

Biosimilars
commercialized

120+

Countries in
commercial
reach

5.8+mn

Patients served
globally

5000+

Employees



www.bioconbiologics.com

Transforming Healthcare. Transforming Lives.

K A L S I S

BUILT TO HELP SENIORS

TURNING YOUR HOME INTO YOUR SOURCE OF STRENGTH, FUNDING YOUR BATTLE AND FUTURE AHEAD

To the warriors determined to beat cancer — we are here for you.

We recognise escalating healthcare costs can be a barrier for retirees with limited savings or insurance.

That's why together with **Kenanga Investors Berhad**, we created KALSIS to help support you on your cancer journey and a brighter future ahead.

Because there is so much to live for.

ELIGIBILITY

- 60 years old and over
- Owner-occupier of a fully-paid, freehold and landed home in Klang Valley
- Current or past cancer patient

FEATURES

- Lumpsum payout (10% of home sale price)
- Annual / Monthly Lifetime Payouts (3.27 - 4% of home sale price)
- Lifetime residence of home and complimentary services for home



VISIT US AT

www.kalsis.com.my



+6011 5638 8580

The full structure of KALSIS (the "Scheme") is still under consideration and the information set out herein may not be accurate, correct or exact depending on the final structure of the Scheme. KALSIS reserves the right to revise or amend any aspects of the Scheme. The final specifications, features, and performance of the Scheme will be set out in the Scheme Documents. It is not advisable to subscribe to, and no decision to participate in the Scheme, should be made based solely on the illustration and the information set out herein. No warranty, whether express or implied, is given regarding the accuracy, completeness, reliability, or suitability of the information provided in this document.



**A COMPANION
TO SUPPORT YOU IN YOUR CANCER DISEASE
JOURNEY WHEREVER YOU MAY GO**



THERAPEUTIC AREAS

- Breast Cancer
- Chronic Myeloid Leukemia
- Myeloproliferative Neoplasm




**Psychosocial
Support**



**Wellness
Journal**



**Medication &
Appointment
Reminder**



**Disease
Information
& Resources**



**Information
About
Medications**



**Support
Group &
Healthcare
Directory**



FAQ



AVAILABLE IN

- English
- Malay
- Mandarin

SCAN ME

Download on the
App Store

GET IT ON
Google Play

Experience personalized and
patient-centric healthcare
with iCanCare

Download the app today!

*Intended for patients and caregivers only



NOVARTIS

This is a non-promotional material and is distributed for educational and/or disease awareness purposes only.
Novartis Corporation (Malaysia) Sdn Bhd
Level 18, Imazium, No. 8, Jalan SS2/37 Damansara Uptown, 47400 Petaling Jaya, Selangor, Malaysia
Tel: +6 03-7662 7777 Fax: +6 03-7662 7000 Website: www.novartis.com.my

ICC/LBM/2025-APR/PA-1036685(m)



National Cancer Congress Malaysia - NCCM




ncc.malaysia



National Cancer Society Malaysia

At MSD, We Are Unified Around Our Purpose

We use the power of leading-edge science to save and improve lives around the world. For more than a century, we've been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world's most challenging diseases.



ONCOLOGY

We're working to invent a world where cancer isn't just treated but cured.

We're proud to deliver breakthrough innovations in oncology that are helping to extend the lives of patients with certain types of cancer. We're continuing to accelerate what we can achieve for the patients we serve, because everyone needs more ways to treat their cancer and, hopefully, more time.

Globally, more than 1 million patients have been treated with MSD oncology medicines over the past five years.

Our medicines are being studied in over 2K+ clinical trials and in more than 30 types of cancer.

VALUE OF VACCINES

Vaccines are vital in the global fight against certain infectious diseases. But a vaccine does no good if it cannot be delivered to the people who need it. It is vital to build resilient immunization programs that expand knowledge of, improve confidence in, and provide access to vaccinations.

Vaccines have helped to prevent 25+ infectious diseases across the globe.

"With the exception of safe water, no other modality, not even antibiotics, has had such a major effect on mortality reduction and population growth."

Susan L. Plotkin and Stanley A. Plotkin, MD, Vaccine Developer, Emeritus Professor of Pediatrics, University of Pennsylvania, Adjunct Professor, Johns Hopkins University



HOSPITAL, SPECIALTY AND CHRONIC CARE

Innovating for patients with the hope of creating a better world

Hospital and specialty care is one of our current key growth pillars. We are also focused on finding solutions for unmet needs in HIV and infectious diseases.

We have a legacy in cardiovascular disease and continue to advance our pipeline in this space.

35+ years committed to research to help combat the challenges of the HIV epidemic.

40+ investigator-initiated antimicrobial stewardship programs funded across the globe.

Connect with us on social



Copyright © 2024 Merck & Co., Inc., Rahway, NJ, USA and its affiliates.
All rights reserved. MY-NON-00155 Aug/2024



National Cancer Congress Malaysia - NCCM



ncc.malaysia



National Cancer Society Malaysia

Unlocking the power of science for people, society and planet

Delivering a pipeline of life-changing medicines,
working towards more effective treatment and
prevention and, ultimately, a cure for some of the
world's most complex diseases

AstraZeneca 

AstraZeneca Sdn Bhd (69730-X)
The Bousteador, Level 12
No.10, Jalan PJU 7/6, Mutiara Damansara
47800 Petaling Jaya, Selangor, Malaysia
MY-12423_SEP2023



More time with the
people we love.

Our work gives people more time with their loved ones. And for over 125 years, it's what always drives us to continue to innovate. We put healthcare's unsolved challenges at the heart of our business because it's where we can make the biggest difference.

www.roche.com.my

Roche (Malaysia) Sdn. Bhd.
Co. Reg. No. 197201000194 (11792-H)
Level 21, The Pinnacle,
Persiaran Lagoon, Bandar Sunway,
47500 Subang Jaya, Selangor Darul Ehsan
Tel: +603 - 7628 5600 | Email: malaysia.pharma@roche.com

M-MY-00003309-06-2025
Expires: 10-06-2027 unless superseded by a new version

EARLY DETECTION SAVES LIFE

More accurate than tumor markers ^{1,2,3}

Latest technology detecting circulating tumor DNA (ctDNA) in Blood

Clinically Validated ^{1,2}

Convenient simple blood test without fasting

Reference: (1) Nguyen, et al. "Analytical and clinical validation of a ctDNA based assay for multi-cancer early detection" (2023). doi:10.1001/2023.02.22.23300420. (2) Nguyen, et al. "Prospective validation study: a non-invasive circulating tumor DNA based assay for simultaneous early detection of multiple cancers in asymptomatic adults" (2023). doi:10.1101/2023.05.05.23280291. (3) JMA News. (2023). Cancer Marker Tests - Are They Accurate? <https://www.jma.edu.my/jma-news/cancer-marker-tests-are-they-accurate/>. Last accessed: 15 November 2024.



Now Available in
**National Cancer Society Malaysia (NCSM)
and selected private hospitals/GPs.**
Speak to your healthcare professional to learn more.

SPOT-MAS 10

A breakthrough in Multi-Cancer Early Detection

Spot early signals of 10 cancers using next generation of ctDNA technology



Colorectum



Esophagus



Lung



Ovary



Head & Neck



Pancreas



Stomach



Endometrium



Breast



Liver-Biliary tract

Single-Cancer Early Detection

SPOT-MAS Lung

New Hope To Outsmart Lung Cancer



A smart blood-based test for routine lung cancer screening by applying AI to check DNA from lung cells.

90% Sensitivity⁽⁴⁾ **92%** Specificity⁽⁴⁾

(4) Nguyen, Van Thien Chi et al. Cost-Effective Shallow Genome-Wide Sequencing for Profiling Plasma ctDNA Signatures In Lung Cancer Detection (January 10/2023). doi:10.1101/2023.01.10.23280291

SPOT-MAS CRC

New Hope To Outsmart Colorectal Cancer



A smart blood-based test for routine cancer screening by applying AI to check DNA from cells.

81% Sensitivity **92%** Specificity

Gene Solutions Genomics Malaysia Sdn. Bhd.

Common Ground, G.016, Jaya One, The Square, 72A, Jln Profesor Diraja Ungku Aziz Seksyen 13, 46200 Petaling Jaya, Selangor, Malaysia

infomy@genesolutions.com

www.genesolutions.com



A Multi-Award Winning, Certified Print & Digital Media Company in Malaysia

OUR SERVICES



Flyer Distribution



Pocket Tissue Advertising



Event Management



Bunting & Banner Installation



Inkjet & Offset Printing



Indoor Digital Media (IDM)
*over 700 indoor TV screen nationwide



Billboard



Table Sticker Advertising



Mobile and Web-Based Applications and Website Development

Contact Us Now For More Information

+6016-211 9810 (Jessie) | +6016-229 5128 (Vivian)



National Cancer Congress Malaysia - NCCM



ncc.malaysia



National Cancer Society Malaysia



**Your One-Stop Life Science
Solutions Provider**



**Your Trusted Oligo
Synthesis Partner**

NEXT GENE SCIENTIFIC is a premier life science and molecular diagnostic solutions provider in Malaysia. Our expertise extends to Oligo synthesis - Oligomy, ensuring comprehensive support for your research endeavors. We are also associated with world-renowned manufacturers of life science reagents and instruments, allowing us to cater to your research needs and help you achieve outstanding and successful results.



WhatsApp Us Now

PRODUCTS & SERVICES



Scientific Equipment

- Oxford Nanopore Next Generation Sequencing
- 10x Genomics Single-Cell & Spatial Transcriptomics
- abCycler PCR
- abCyclerQ qPCR
- abGenix Automated DNA/ RNA Extraction
- RoboSep™ Automated Cell Isolation
- Easy Cell Analyzer
- Nucleofector® Transfection



Molecular Biology

- Restriction Enzymes
- Luna® qPCR Reagents
- DNA/RNA Purification Kits
- Gel Electrophoresis
- PCR Essentials
- CRISPR
- Cloning Essentials
- NGS Reagent
- RNA Synthesis & Modification



Microbiology

- Agar and Broth
- Selective Supplement
- Ready Made Media
- Antibiotic Disc
- Gas Generation System
- Microbe Identification System
- Staining Reagent
- Halal Identification Kit
- ATCC® Quality Control Organisms



Cell Biology

- Primary Cells
- Stem Cells
- Culture Media, eg. DME
- Supplement, eg. FBS
- Specialized Media for Primary & Stem Cells
- Small Molecules
- Cell Isolation
- Transfection
- Cell Dissociation
- Cryopreservation



Molecular Diagnostics

- NGS Cancer Panel
- NGS for Pathogenic Microorganisms, eg. MTB, NTM, Fungal, Central Nervous System & PAN Infections
- Pre-implantation Genetic Testing (PGT) Solutions
- HLA Typing
- Thalassemia
- Respiratory Infections
- Tropical Infections
- Zoonotic Diseases



Proteins & Custom Services

- Protein Expression, Purification & Interaction
- Protein Electrophoresis & Western Blotting Essentials
- Antibodies & ELISA
- Metabolism Assay Kit
- Recombinant Proteins
- Oligo & Probe Synthesis
- Sanger & Next Generation Sequencing (NGS)
- Antibody Production
- DNA & Gene Synthesis
- Peptide Synthesis

sales@nextgene.my

+603-8051 5106

www.nextgene.my

Next.Gene.Scientific

nextgenescientific

Next Gene Scientific



National Cancer Congress Malaysia - NCCM



ncc.malaysia



National Cancer Society Malaysia



GROWING POTENTIALS

At Berjaya, we aspire to be a leading global consumer group that brings together sustainable products and brands through four key business segments, namely Retail (Food and Non-Food), Hospitality, Property and Services.



Berjaya Corporation Berhad [Registration No. 200101019033 (554790-X)]
Level 12 West, Berjaya Times Square, No. 1 Jalan Imbi 55100 Kuala Lumpur, Malaysia
☎ (603) 2149 999 ☎ www.berjaya.com

Our Services



Individual

Medical Consult & Treatment
Annual Health Surveillance
Rapid Investigation (Full Blood Count , Dengue, HIV & Pregnancy)
Electrocardiogram
Non-invasive Transcutaneous Bilirubin Test
Pap Smear
Nebuliser
Suction
Toilet & Suturing For Minor Wounds
Wound Care
Adult & Child Vaccination
Ultrasound Scan
Family Planning (Intramuscular Depo & Oral Contraception)

Company

Pre-employment Medical Check-up
Annual Health Surveillance
Onsite Vaccination

Community

Health awareness talk
Health campaign
Onsite Vaccination

Headquarter 總部

-  +6011-36597608
-  asclepius.hc@gmail.com
-  Asclepius Healthcare Clinic 友德醫務所
-  @asclepius.hc
-  376, Jalan Simbang, Taman Perling, 81200, Johor Bahru, Johor
-  Everyday 8am - 12am

Kulai Branch 古來分行

-  +601121722899
-  asclepiuskulai@gmail.com
-  Asclepius Healthcare Clinic 友德醫務所 Kulai Branch 古來分行
-  @asclepius.hckulai
-  26GF, Jalan Tropika 1, Taman Tropika, Kulai, Malaysia
-  Everyday 8am - 10pm


Sri Tebrau Branch 大馬分行

-  +601169923296
-  asclepiustebrau@gmail.com
-  Asclepius Healthcare Clinic 友德醫務所 SriTebrau Branch大馬分行
-  @asclepius.hc_sritebrau
-  41 GF Jalan Perisai Taman Sri Tebrau 80050 Johor Bahru Johor
-  Everyday 8am - 12am

Transforming your life with healing touch

The New Generation of Soya Nutrition

One glass of
HOMESOY™ 3.0
 equals to



BOOTH LAYOUT

- A1:** Biocon Biologics Limited
A2: National Cancer Society Malaysia
A3: TATA Consultancy Services
A4: AXIOS International
- B1:** Breast Cancer Welfare Association
B2: Hong Kong Anti-Cancer Society
B3: VitaHealth
B4: Gene Solutions
B5: Next Gene Scientific
B6: Compai Pharma
B7: SBS Digital Holdings Sdn Bhd
B8: KALSIS
B9: KALSIS
B10: Asclepius Healthcare Clinic
B11: Lafre Global Sdn Bhd
B12: Roche
B13: MSD
B14: Novartis
B15: United Imaging Group
B16: United Imaging Group
B17: CORUM
B18: Theta Edge Berhad



JOIN US FOR THE NATIONAL CANCER CONGRESS MALAYSIA 2025

SCAN QR CODE TO REGISTER



BRIDGING GAPS, BUILDING HOPE, EMPOWERING LIVES